Immusoft Corporation

Oisin Biotechnologies, Inc.

Sigma Genetics, Inc.

Matthew Rein Scholz

Eric J Herbig

Mei Xu

David Edwin Kirtley

Gary Charles Hudson

Christopher James Pihl

John David Lewis

Rian De Laat

Provided nucleic acid-based expression construct for the target cell-specific production of a therapeutic protein, such as a pro-apoptotic protein, within a target cell, including a target cell that is associated with aging, disease, or other condition, in particular a target cell that is a senescent cell or a cancer cell. Also provided are formulations and systems, including fusogenic lipid nanoparticle (LNP) formulations and systems, for the delivery of nucleic acid-based expression constructs as well as methods for making and using such nucleic acid-based expression constructs, formulations, and systems for reducing, preventing, and/or eliminating the growth and/or survival of a cell, such as a senescent cell and/or a cancer cell, which is associated with aging, disease, or other condition as well as methods for the treatment of aging, disease, or other conditions by the in vivo administration of a formulation, such as a fusogenic LPN formulation, comprising an expression construct for the target cell-specific production of a therapeutic protein, such as a pro-apoptotic protein, in a target cell that is associated with aging, disease, or other condition, in particular a target cell that is a senescent cell or a cancer cell.

Fusogenic lipid nanoparticles for target cell-specific production of a therapeutic protein

Expression constructs, fusogenic lipid-based nanoparticles and methods of use thereof

A system includes a control device and a magnetic device coupled to the control device. The magnetic device is configured to inductively couple to a treatment target including one or more cells exposed to an agent, and includes one or more magnetic coils. The control device and the magnetic device are collectively configured to generate and apply a transient magnetic field to the treatment target to induce an electric field and porate the one or more cells and to permit the agent to enter the one or more cells.

Systems, devices, and methods for electroporation induced by magnetic fields

The present disclosure relates to the in vitro differentiation of memory B cells to plasmablasts or plasma cells and genetic modification of these cells to express a protein of interest, such as a specific antibody or other protein therapeutic.

Methods for in vitro memory B cell differentiation and transduction with VSV-G pseudotyped viral vectors

The present disclosure provides compositions and methods for transducing B cells. In particular, the present disclosure provides for vectors and methods for transducing resting B cells and methods for differentiating same to express a transgene of interest.

Vectors and methods for transducing B cells

Growing community of inventors

Seattle, WA, United States of America

Matthew Rein Scholz